Aligned Bio secures SEK 19.4 million to scale up its groundbreaking nanowire technology
Kenneth Harlow, Ph.D., CEO of Aligned Bio
Lund, Sweden – SmiLe company Aligned Bio has successfully completed a financing round, securing SEK 19.4 million to accelerate the development and scale up its nanowire production technology. The company has been accepted into the SmiLe incubator program.
The nanotechnology company Aligned Bio has completed a new share issue to take its unique platform for manufacturing semiconductor nanowires toward commercialization. Both existing shareholders and new investors, including SmiLe Inject Capital, participated in the financing round.
What makes Aligned Bio’s technology unique is its ability to detect individual molecules, significantly improving sensitivity in the analysis of biomolecules. The production of nanowires also becomes simpler and thus more cost-effective than with existing techniques. The company is now starting to scale up production.
The potential applications are broad, but initially, the company is focusing on two key areas: single-molecule DNA analysis and highly sensitive assays, for example, point-of-care diagnostics of a specific biomarker for suspected heart attack.
Aligned Bio is conducting projects in collaboration with leading players in the diagnostics industry, including Roche Diagnostics. The company is also collaborating with other international companies that recognize the potential to integrate nanowire technology into their products.
”We believe that our DNA analysis technology will soon be mature enough to attract a partner who can help us bring it to market. I am very much looking forward to leveraging SmiLe’s extensive network and expertise in business development. Moreover, their laboratories and equipment give us access to the instruments we really need,” says Kenneth Harlow, CEO of Aligned Bio.
"We are very pleased that Aligned has been so successful with its financing. This enables their groundbreaking products to reach the market sooner and benefit patients. We look forward to being involved and supporting the company's path forward,” says Ulrika Ringdahl, CEO of SmiLe Venture Hub.
For more information, please contact:
Ulrika Ringdahl, CEO of SmiLe Venture Hub, +46 73 656 62 32, ulrika.ringdahl@smileincubator.life,
or
Kenneth Harlow, CEO of Aligned Bio, +46 70 777 00 43,
kenneth.harlow@alignedbio.com,
About SmiLe Venture Hub – Pioneering Life Science Innovations
SmiLe is a leading venture hub that specializes in advancing life science startups from concept to commercialization. We offer comprehensive support through every stage of entrepreneurship, including tailored incubation and acceleration programs, a variety of educational courses, and access to top-tier lab facilities. To date, our flagship incubator program has supported over 100 startups, facilitating their collective acquisition of more than EUR 841 million in venture capital and contributing to 21 successful IPOs. Recognized as one of Europe’s leading startup hubs in 2024 by the Financial Times and Statista, SmiLe continues to be a catalyst for innovation in the life sciences sector. As a non-profit entity based in Lund, Sweden, SmiLe is supported by Region Skåne, Lund Municipality, Lund University, and Medicon Village. We are also backed by our sponsors Agilent, Sparbanken Skåne, Høiberg, Setterwalls, Zacco, Key2Compliance, Phase Holographic Imaging, ChemoMetec, Samplix, and Qiagen. For more information: www.smileventurehub.com
Powered by Notified